Dual aromatase-steroid sulfatase inhibitors

L. W. Lawrence Woo, Christian Bubert, Oliver B. Sutcliffe, Andrew Smith, Surinder K. Chander, Mary F. Mahon, Atul Purohit, Michael J. Reed, Barry V. L. Potter

Research output: Contribution to journalArticlepeer-review

75 Citations (Scopus)

Abstract

By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated. The best DASIs in vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82 nM; IC50(sulfatase) = 39 nM), and 14, (IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM). X-ray crystallography of 5, and docking studies of selected compounds into an aromatase homology model and the steroid sulfatase crystal structure are presented. Both 5 and 14 inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose. Almost complete dual inhibition is observed for 5 but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h. DASI 5 did not inhibit aldosterone synthesis. The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.
Original languageEnglish
Pages (from-to)3540-3560
JournalJournal of Medicinal Chemistry
Volume50
Issue number15
DOIs
Publication statusPublished - 2007

Fingerprint Dive into the research topics of 'Dual aromatase-steroid sulfatase inhibitors'. Together they form a unique fingerprint.

Cite this